New Healthcare research report from Business Monitor International is now available from Fast Market Research
Boston, MA -- (SBWIRE) -- 10/28/2013 -- We expect pressures on the French government to mount over the coming quarters encouraging it to engage in more concerted fiscal consolidation, particularly as lower growth begins to translate into lower government revenues. We believe that the pharmaceuticals and healthcare sector, which is a recipient of a large proportion of public funds, will be a target of the government's cost containment efforts. While France has not fallen prey to the bond vigilantes thus far, unlike the peripheral countries of the eurozone, the country nonetheless has one of the largest public sector debt piles in Europe and remains susceptible to contagion effects.
View Full Report Details and Table of Contents
Headline Expenditure Projections
- Pharmaceuticals: EUR34.17bn (US$43.40bn) in 2012 to EUR33.02bn (US$43.91bn) in 2013; -3.4% in local currency terms and 1.2% in US dollar terms.
- Healthcare: EUR237.74bn (US$301.93bn) in 2012 to EUR243.95bn (US$297.61bn) in 2013; +1.9% in local currency terms and -2.1% in US dollar terms.
Risk/Reward Ratings: France remains ranked fourth out of the 13 markets in BMI's Western Europe Pharmaceutical Risk/Reward Ratings (RRR) matrix for Q313, with a composite score, at 70.1 out of the maximum 100 points. The country's reward profile remains considerably less attractive than its risk score, reinforcing our view of the country's potential due to a stronger emphasis on the regulatory environment, which we regard as a major factor affecting the business environment for drugmakers, rather than on the basis of real opportunities for higher per-capita drug consumption.
Key Trends And Developments
National health insurance data published by the LEEM (les entreprises du medicament) revealed that between 2005 and 2013, cost containment policies implemented in the healthcare sector resulted in the greatest savings being achieved in pharmaceutical spending (EUR1.14bn, US$1.52bn) on average annually compared to other areas of insurance expenditure - hospitals and clinics (EUR422mn, US$562mn), clinical laboratories (EUR97mn, US$129mn), medical devices (EUR60mn, US$80mn), healthcare transport facilities (EUR56mn, US$74mn) and physiotherapy (EUR25mn, US$33mn).
In Q213, multinational drugmaker Sanofi recorded sales of EUR8.00bn (US$10.59bn), a 9.8% decrease on reported basis terms (-6.3% in constant exchange rate (CER) terms). In the second quarter, sales for the Pharmaceuticals business (the company's largest division by revenue) were EUR6.71bn (US$8.88bn), a decrease of 7.1%, attributed to generic competition, EU austerity measures and an adjustment of EUR122mn (US$161mn) related to Brazil. Inventory in Brazil was 'significantly and inappropriately' higher than necessary, resulting in Sanofi recalling expiring stock. The Consumer Healthcare division recorded sales of EUR729mnn (US$965mn) (+1.8%) and the Generics division recorded sales of EUR300mn (US $397mn) (-36.8%).
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Healthcare research reports at Fast Market Research
You may also be interested in these related reports:
- Nigeria Pharmaceuticals & Healthcare Report Q4 2013
- Kenya Pharmaceuticals & Healthcare Report Q4 2013
- Kuwait Pharmaceuticals & Healthcare Report Q4 2013
- Croatia Pharmaceuticals & Healthcare Report Q4 2013
- Estonia Pharmaceuticals & Healthcare Report Q4 2013
- Latvia Pharmaceuticals & Healthcare Report Q4 2013
- Hungary Pharmaceuticals & Healthcare Report Q4 2013
- Singapore Pharmaceuticals & Healthcare Report Q4 2013
- Pakistan Pharmaceuticals & Healthcare Report Q4 2013
- Lebanon Pharmaceuticals & Healthcare Report Q4 2013